White blood cell population dynamics
Systems and methods for modeling and detecting white blood cell population dynamic for diagnosis and treatment, e.g., of acute coronary syndrome or leukocytosis.
1. A method comprising:
receiving data indicative of a property value of each white blood cell (WBC) in a sample of white blood cells (WBCs) of a patient, wherein the data comprises single-cell measurements from a complete blood count;
determining, using parameter estimation, a value indicative of WBC population dynamics of the patient based on the data indicative of the property value of each WBC.
2. The method of claim 1 , wherein the data comprises optical, fluorescence, or impedance single-cell measurements from a complete blood count.
3. The method of claim 1 , wherein the data is indicative of a morphological property or intracellular composition of each WBC in the sample.
4. The method of claim 1 , wherein the data comprise one or more of Axial Light Loss (ALL) representing cell size; Intermediate Angle Scatter (IAS) representing cellular complexity; Polarized Side Scatter (PSS) representing nuclear lobularity; Depolarized Side Scatter (DSS) distinguishing granulocytes (neutrophils and eosinophils); and a fluorescence signal separating nucleated red blood cells, stromal cells and the mononuclear agranulocytes (lymphocytes and monocytes).
5. The method of claim 4 , wherein the data are used to determine one or more values selected from the group consisting of aALL, DALL, aIAS, DIAS, KPSS, aSSC,L, aSSC,M, aRNA/DNA,L, DSSC,L, DSSC,M, and DRBA/DNA,L.
6. The method of claim 5 , further comprising comparing the one or more values to a reference value.
7. The method of claim 6 , wherein the reference value represents an identified cohort of subjects, or a value determined at an earlier or later point in time in the same subject.
8. The method of claim 1 , wherein the WBCs are selected from the group consisting of neutrophils, lymphocytes, and monocytes.
9. The method of claim 1 , further comprising receiving data indicative of a complete blood count of the patient, wherein receiving the data indicative of the complete blood count comprises receiving the data indicative of the property value of each WBC.
10. The method of claim 1 , wherein the property value of the parameter is estimated based on data indicative of a predefined normalized property value of WBCs.
11. The method of claim 1 , further comprising:
receiving data indicative of a first complete blood count of the patient in which the property value of each WBC in a first sample of WBCs is measured, and
receiving data indicative of a second complete blood count of the patient in which the property value of each WBC in a second sample of WBCs is measured,
wherein the value of the parameter is estimated based on the data indicative of the first complete blood count and the data indicative of the second complete blood count.
12. The method of claim 1 , further comprising:
receiving data indicative of a normal template or ensemble of normal complete blood counts in which the property value of each WBC in a first sample of WBCs is measured, and
receiving data indicative of a second complete blood count from the patient in which the property value of each WBC in a second sample of WBCs is measured,
wherein the value of the parameter is estimated based on the data indicative of the first complete blood count and the data indicative of the second complete blood count.
13. The method of claim 1 , wherein the property value is indicative of a property of each WBC selected from the group consisting of cell size, cytoplasmic granularity, morphology, nuclear morphology, and nuclear granularity.
14. The method of claim 1 , wherein receiving the data indicative of the property value of each WBC comprises receiving data indicative of axial light loss measurements of the sample of WBCs, intermediate light loss measurements of the sample of WBCs, or polarized side scatter measurements of the sample of WBCs.
15. The method of claim 1 , wherein the parameter indicative of the WBC population dynamics of the patient is indicative of a drift or a diffusion of the WBC population dynamics.
16. The method of claim 1 , further comprising providing information for treatment or diagnosis of a condition of the patient associated with an inflammatory or immune system response based on the parameter.
17. The method of claim 16 , wherein the condition is selected from the group consisting of a hematological malignancy, acute coronary syndrome, urinary tract infection, and an autoimmune disease.
18. The method of claim 16 , wherein providing information for treatment or diagnosis of a condition of the patient associated with an inflammatory immune system response based on the parameter comprises providing information for treatment or differential diagnosis of reactive leukocytosis and malignant leukocytosis.
19. The method of claim 1 , wherein a troponin level of the patient is within normal range, and or a WBC count is within normal range.